Scheme 2. Synthesis of (2R,3R)-2-(2,4-Difluorophenyl)-3-(piperazin-1-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol (6).
Fungal infection became an important complication and a major cause of morbidity and mortality in immunocompromised individuals suffering from tuberculosis, cancer or AIDS and in organ transplant cases.
1 These infections are often induced by opportunistic causative fungi that are not normally pathogenic and commonly live in the patient's body or are commonly found in the environment. The key opportunistic fungal pathogens were Candida albicans, Aspergillus fumigatus and Cryptococcus spp., which cause mucormycosis, a rapidly fatal infection especially in immunocompromised patients. Triazole antifungals which act by inhibiting lanosterol cytochrome P-450 14 α-demethylase (CYP51) have now become the most rapidly expanding group of antifungal compounds. These drugs are orally active, show a broad-spectrum against most yeasts and filamentous fungi, and are relatively nontoxic. However, the increase of opportunistic fungal infections and emergence of azole resistance strains have intensified the work of medicinal chemists to develop new antifungal drugs.
2
Hence, novel triazole compounds are prepared with different substituents on (1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl moiety. The present study on the synthesis and antifungal activity of new voriconazole analogues which are incorporated indole derivatives. A variety of indole derivatives with different substituents could exhibit the biological activities through different action and sometimes improve upon the activities. For example, the synthesis and antifungal activity of 1-halogenobenzyl-3-imidazolylmethylindole derivatives showing various degrees of antifungal against Candida albicans and Aspergillus fumigatus strains was repored.
3 The presence of halogen and halogenobenzyl group on the indole ring was considerably important factor to affect their antifungal activity. Based on this speculation, indoleconazole derivatives were synthesized and were evaluated their antifungal activity.
The synthesis of indole moiety was proceded by general methods as shown in Scheme 1. 5-,6-or 7-substituted indoles 1 were formylated with dimethylformamide using phosphorus oxychloride as a catalyst. The yield of aldehyde 2 is nearly quantitative, and the product is obtained in a state of high purity. 1-Substituted indole derivatives 3 were obtained by the nucleophilic substitution of 3-formyl-1-H indole 2 with appropriate substituted benzyl bromides(or chlorides) or alkyl chlorides in the presence of the base such as NaH and K2CO3. 3-Piperazinylmethyl indole compounds 4 were obtained using reductive amination conditions.
The optically active key intermediate (2R,3S)-2-(2,4-difluorophenyl)-3-methyl-2-(1H-1,2,4-triazol-1-yl)methyloxirane 5 was derived from R-lactate with a well known method.
5 The piperazine compound 6 was prepared by reacting an oxirane compound 5 with a piperazine in the presence of LiClO 4 in a 50% yield.
Having obtained the key intermediate (5 or 6), the next steps was to couple it with a number of substituted indoles (3 or 4) as shown in Scheme 3. The piperazine compound 6 was reacted with various formylindoles (3) in presence of NaBH(OAc) 3 in dichloromethane at room temperature. Alternatively, the oxirane key compound 5 on reaction with 3-piperazinylmethylindoles (4) in the presence of lithium perchlorate produces the final compounds.
All the newly synthesized compounds 7-39 was assayed for compared to that of Amphotericine B (0.125 μg/mL). The significant activity was found for compounds 8, 10, 19, 27, 32, 38. The presence of 2,4-difluorobenzyl group on 1-position of indole moiety showed better activity than compounds with mono/ dichlorobenzyl or mono-fluorobenzyl substituents on 1-position of indole, and a unsubstituted compound 7. The compounds 8, 10, 19, 27, 32, 38 showed potential activity due the presence of 4-fluorophenyl or 2,4-difluorobenzyl at 1-position of the indole ring.
Notes
The MIC of indole compounds 7-39 against mold fungi were compared with that of itraconazole. The result showed that compound 8 (MIC = 1 μg/mL) and 36 (MIC = 1 μg/mL) had less active than that of itraconazole, but had comparable antifungal profile with amphotericine B against A. fumigatus ATCC16424. However, the MIC values of tested compounds also demonstrated that antifungal activity was decreased considerably when the hydrogen atom at 1-position of indole structure were replaced by an alkyl chain and alcohol group such as sec-butyl (15), methylallyl (16, 24, 35) and propan-2-ol (17, 25, 30).
The substituents (R 1 :F, Cl, CN, N 3 ) on the 5,6,7-position of the indole ring appear to contribute partially to antifungal potency. Interestingly, replacing the hydrogen with a cyano group at the 7-position of indole ring resulted in a promising antifungal activity.
In conclusion, we have synthesized a series of novel substituted indole-conazole compounds. The antifungal profile of these compounds indicated that 2,4-difluorobenzylindole compounds 10, 19, 27, 32, 37, 38 and 4-fluorophenylindole compounds 8, 36 have potent antifungal activity. Among these promising antifungal candidates, (2R,3R)-2-(2,4-difluorophenyl)-3-{4-[1-(4-fluorophenyl)-1H-indol-3-ylmethyl]-piperazin-1-yl}-1-(1H-1,2,4-triazol-1-yl)butan-2-ol (8) and (2R,3R)-2-(2,4-difluorophenyl)-3-{4-[7-cyano-1-(2,4-difluorobenzyl)-1H-indol-3-ylmethyl]-piperazin-1-yl}-1-(1H-1,2,4-triazol-1-yl)butan-2-ol (38) showed better antifungal activity than that of the clinically prevalent antifungal drug fluconazole against C. albicans ATCC64548, ATCC36082, ATCC90028 and the drug-resistant C. albicans ATCC MYA-1003.
The observed antifungal activity was believed to be exerted through specific target because the introduction of the substituent groups on the indole caused differences in the antifungal activity. Therefore, the modification of these compounds is must go on being investigated.
Experimental Section
Synthesis of 1-(2,4-difluorobenzyl)-3-((piperazin-1-yl)methyl)-1H-indole. 1-(2,4-difluorobenzyl)-3-formylindole was prepared according to the method described in Eur. J. Med. Chem. 2003, 38, 75 . To a solution of 1-(2,4-difluorobenzyl)-3-formylindole (1.0 g, 3.7 mmol) and piperazine (637 mg, 7.4 mmol) in dichloromethane, acetic acid was added and the stirred for 30 min. To the mixture, NaBH(OAc) 3 (3.1 g, 14.8 mmol) was added with vigorous stirring and then the resulting mixture was stirred for 24 h. The mixture was extracted with dichloromethane (3 × 20 mL). The combined organic extract was washed with water, brine, dried (Na 2 SO 4 ) and concentrated to give the desired piperazinyl compound in yields of 48%. 1-yl}-1-(1H-1,2,4-triazol-1-yl)butan-2-ol (19) . To a solution of 1-(2,4-difluorobenzyl)-5-fluoro-3-formylindole (0.5 g, 1.7 mmol) and (2R,3R)-2-(2,4-difluorophenyl)-3-(piperazin-1-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol (6) (1.2 g, 3.4 mmol) in dichloromethane, acetic acid was added and the stirred for 30 min. To the mixture, NaBH(OAc) 3 (1.44 g , 6.8 mmol) was added with vigorous stirring and then the resulting mixture was stirred for 24 h. The mixture was extracted with dichloromethane (3 × 20 mL). The combined organic extract was washed with water, brine, dried (Na2SO4) and concentrated to give the desired piperazinyl compound in yields of 48%. 
Synthesis of (2R,3R)-2-(2,4-difluorophenyl)-3-{4-[1-(2,4-difluorobenzyl)-6-chloro-1H-indol-3-yl]methyl)-piperazin-1-yl}-1-(1H-1,2,4-triazol-1-yl)butan-2-ol (32).
A mixture of (2R,3S)-2-(2,4difluorophenyl)-3-methyl-2-(1H-1,2,4-triazol-1-yl)methyloxirane (5) (2.0 g, 7.5 mmol), 6-chloro-1-(2,4-difluorobenzyl)-3-piperazinylmethyl-1H-indole (5.6 g, 15 mmol) and lithium perchlorate (2.4 g, 22.5 mmol) in acetonitrile (100 mL) was heated under reflux for 24 h. The solvent was removed under reduced pressure, the residue was treated with crushed ice and extracted with ethyl acetate (3 × 20 mL). The combined organic extract was washed with water, brine, dried (Na2SO4) and concentrated. The residue was purified by chromatography on silica gel (dichloromethane : ethanol = 1 : 1, v/v) to give (2R,3R)-32 in yields of 65%.
Notes pension of Fungal strains were adjusted to 0.108 of absorbance and was 1:50 diluted with RPMI 1640 medium. Then another 1:20 dilution was made to have 1 × 10 3 -5 × 10 3 CFU/mL. The spore suspensions of the other strains were adjusted with sterile saline to 80 -82% of transmittance and were 1:50 diluted with RPMI 1640 medium to make 0.4 × 10 4 -5 × 10 4 CFU/mL. Autoclaved 96-well microplate was prepared in advance, and 0.1 mL of series of dilutions of the test article and 0.1 mL of spore suspensions were mixed in each well of the microplate to have concentration range of 0.244 -250 mg/mL. And then 25 μL of alarmarblue (Biosource) was added into the well. Two wells were assigned for each concentration level to make duplicates. After 24 hour and 72 hour of incubation, the absorbance bands of the contents of the well were measured with Microplate reader (SOFTmax PRO, Molecular Devices) and observations with the naked eye were also referred. The results were presented as Minimum Inhibitory Concentration (MIC). The concentration of each test strains, at which the growth was inhibited by 80% compared to the negative control, was determined.
